Moreover, RIPK3 and necroptosis might play a role in the response of Eμ-Myc lymphomas (and other tumours) to anti-cancer agents in vivo, perhaps by impacting anti-tumour immune responses from the host, and we will make our cell lines available for such investigations. This evidence concerns the gene RIPK3 and cancer.